Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.

Alzheimer’s Association International Conference 2016, Toronto, Canada

Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Christopher U. Missling

View Poster

Share this: